# Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts

> **NCT00933231** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 281 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** tacrolimus
- **DRUG:** tacrolimus
- **BIOLOGICAL:** Simulect
- **DRUG:** Cellcept
- **DRUG:** Corticosteroids
- **DRUG:** Ramipril
- **DRUG:** Irbesartan

## Key facts

- **NCT ID:** NCT00933231
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08-17
- **Primary completion:** 2015-05-11
- **Final completion:** 2018-04-03
- **Target enrollment:** 281 (ACTUAL)
- **Last updated:** 2024-11-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00933231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00933231, "Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00933231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*